Frazier Life Sciences Acquisition Corp. II (NASDAQ:FLSC) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Frazier Life Sciences Acquisition Corp. II (NASDAQ:FLSC) to a hold rating in a report released on Saturday,Wall Street Zen reports.

Frazier Life Sciences Acquisition Corp. II Price Performance

FLSC stock opened at $10.28 on Friday. Frazier Life Sciences Acquisition Corp. II has a 12 month low of $10.10 and a 12 month high of $10.63.

Insider Transactions at Frazier Life Sciences Acquisition Corp. II

In related news, CEO Albert Cha bought 300,000 shares of the business’s stock in a transaction on Thursday, October 15th. The shares were bought at an average price of $10.00 per share, for a total transaction of $3,000,000.00. Following the completion of the purchase, the chief executive officer directly owned 300,000 shares of the company’s stock, valued at approximately $3,000,000. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Frazier Life Sciences Acquisition Corp. II Company Profile

Frazier Life Sciences Acquisition Corp. II is a special purpose acquisition company, or SPAC, focused on identifying and combining with a business in the life sciences sector. The company does not operate a conventional commercial business and was formed to pursue a merger, acquisition, or similar business combination.

Its target opportunities may include companies involved in biotechnology, pharmaceuticals, medical devices, diagnostics, or other healthcare-related technologies. The company’s objective is to provide a publicly traded platform for a private life sciences business through a business combination.

Frazier Life Sciences Acquisition Corp.